Abstract
Background: There is limited data on moderate-dose with slow-infusion thrombolytic regimen by ultrasound-asssisted-thrombolysis (USAT) in patients with acute pulmonary embolism (PE).
Aims: In this study, our eight-year experience on USAT with moderate-dose, slow-infusion tissue-type plasminogen activator (t-PA) regimen in patients with PE at intermediate-high- and high-risk was presented, and short-, and long-term effectiveness and safety outcomes were evaluated.
Methods: Our study is based on the retrospective evaluation of 225 patients with PE having multiple comorbidities who underwent USAT.
Results: High- and intermediate-high-risk were noted in 14.7% and in 85.3% of patients, respectively. Mean t-PA dosage was 35.4±13.3 mg, and the infusion duration was 26.6±7.7 h. Measures of pulmonary artery (PA) obstruction and right ventricle (RV) dysfunction were improved within days (p<0.0001 for all). During the hospital stay, major and minor bleeding and mortality rates were 6.2%, 12.4%, and 6.2%, respectively. Bleeding and unresolved PE accounted for 50% and 42.8% of in-hospital mortality, respectively. Age, rate, and duration of t-PA were not associated with in-hospital major bleeding and mortality. Oxygen saturation exceeded 90% in 91.2% of patients at discharge. During follow-up of median 962 (610-1894) days, high-risk status related to 30-day mortality, whereas age >65 years was associated with long-term mortality.
Conclusion: Our real-life experience with USAT with moderate-dose, slow-infusion t-PA regimen in patients with PE at high-and intermediate-high risk demonstrated clinically relevant improvements in PA obstructive burden and RV dysfunction. Age, rate or infusion duration of t-PA was not related to major bleeding or mortality risk, whereas unresolved obstruction remained as a lethal issue.
Keywords: Ultrasound assisted thrombolysis, catheter directed thrombolysis, pulmonary embolism, bleeding, mortality, tissue plasminogen activator.
Graphical Abstract
[http://dx.doi.org/10.1093/eurheartj/ehu283] [PMID: 25173341]
[http://dx.doi.org/10.1183/13993003.01647-2019] [PMID: 31473594]
[http://dx.doi.org/10.1093/eurheartj/ehy873] [PMID: 30590531]
[http://dx.doi.org/10.1183/13993003.01775-2017] [PMID: 29348184]
[http://dx.doi.org/10.1001/jama.2014.5990] [PMID: 24938564]
[http://dx.doi.org/10.1093/eurheartj/ehu218] [PMID: 24917641]
[http://dx.doi.org/10.1097/00000658-197112000-00001] [PMID: 5132432]
[http://dx.doi.org/10.1016/j.jvir.2009.08.002] [PMID: 19875060]
[http://dx.doi.org/10.1378/chest.15-0119] [PMID: 25856269]
[http://dx.doi.org/10.1111/jocs.12354] [PMID: 24827636]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005544] [PMID: 24226805]
[http://dx.doi.org/10.1093/eurheartj/eht531] [PMID: 24334719]
[http://dx.doi.org/10.1016/j.jcin.2015.04.020] [PMID: 26315743]
[http://dx.doi.org/10.23736/S0392-9590.17.03775-0] [PMID: 28206731]
[http://dx.doi.org/10.1177/0003319716661446] [PMID: 27485362]
[http://dx.doi.org/10.4244/EIJ-D-18-00371] [PMID: 30082262]
[http://dx.doi.org/10.2174/1570161115666170404122535] [PMID: 28393706]
[http://dx.doi.org/10.1161/CIR.0000000000000707] [PMID: 31585051]
[http://dx.doi.org/10.1016/j.amjcard.2019.07.040] [PMID: 31492420]
[http://dx.doi.org/10.1177/1358863X19838334] [PMID: 30915914]
[http://dx.doi.org/10.1016/j.jcin.2018.04.008] [PMID: 30025734]
[http://dx.doi.org/10.1161/CIRCINTERVENTIONS.120.009012] [PMID: 32757658]
[http://dx.doi.org/10.2214/ajr.176.6.1761415] [PMID: 11373204]
[http://dx.doi.org/10.1111/j.1538-7836.2009.03678.x] [PMID: 19878532]